Beyond HEK293 — Terry Hébert on iPSC-Derived GPCR Models, Live April 16,
- Yamina Berchiche
- 2 days ago
- 4 min read
The gap between pharmacological screening and clinical translation has a structural explanation. Generic cell systems (usually) generate clean data — but they don't reflect the tissue environment, disease context, or signaling complexity that determines whether a compound actually works.
This week's session examines what changes when you close that gap.
Terry Hébert joins the Dr. GPCR community live on April 16 — one of 12+ Masterclasses planned for 2026, all included in Premium.
Also this week: Terry Kenakin's AMA on binding mode differentiation, the GPCR community in Boston on April 29, and the GPCRs Drug Discovery Summit April 28-30.
iPSC-Derived GPCR Models: Beyond HEK293 for Translational Pharmacology
HEK293 systems have driven pharmacological screening for decades — and for good reason.
They are scalable, reproducible, and well-characterized.
But they have a structural limitation when signaling outcomes depend on cell type, signaling complex assembly, and disease biology. The data they generate reflects the cellular background of the expression system, not the tissue or disease context in which the receptor operates.
This gap becomes consequential when translational interpretation depends on receptor behavior in environments where protein expression levels, membrane composition, and accessory protein availability differ substantially from standard screening conditions.
Patient derived iPSC's, organoid systems, and biosensor-based assays introduce models that better preserve the biological context of GPCR signaling. In these systems, receptor pharmacology can be examined alongside disease-relevant phenotypic responses.
This session with Terry Hébert will cover how patient-derived induced pluripotent stem cells (iPSCs), organoid systems, and biosensor-based assays extend GPCR pharmacology into disease-relevant environments, and what the implications are for translational pharmacology
programs.
In 48h : April 16, 2026, 10 AM EST.
This live session with recording available as well as all masterclasses are now included in Premium.
Terry's Corner AMA — How Important Is It to Know Where Your Molecule Binds?
The binding mode of a new molecule isn't a footnote in pharmacology. It determines what the molecule actually does to the system. An orthosteric molecule binds to the natural agonist site, hijacking the target and imposing its own efficacy. An allosteric molecule works in concert with natural signaling, producing a fundamentally different pharmacological pattern — with different consequences for assay design, data interpretation, and pipeline decisions.
These are not two versions of the same outcome.
They are fundamentally different modes of action.
In this month's AMA, Terry Kenakin walks through the methods used to differentiate orthosteric from allosteric binding modes, and why establishing that distinction early carries immense practical value for drug discovery programs at any stage.
Thursday, April 16, 1:00 PM ET — note the adjusted time.
Bring the question you've been sitting on. Dr. Kenakin is in the room.
Send your questions ahead of time to Terry@DrGPCR.org
Free for Kenakin Brief subscribers. Sign up to get access ➤
Dr. GPCR at the GPCRs Targeted Drug Discovery Summit — Boston, April 28-30
The GPCRs Targeted Drug Discovery Summit brings together scientists working at the intersection of GPCR biology and therapeutic development. This year the meeting is in Boston, April 28-30 — and I will be there.
What draws me to this meeting is not just the science on the program, but the conversations that happen around it. The questions that don't make it into talks. The data that's too early to present but too important not to discuss. The field moves in those moments as much as it does on stage.
If you're attending, find me — we're also organizing something for the GPCR community in Boston on April 29. Stay tuned.
This Week's Scientific Highlight
GRKs and arrestins play a critical role in GPCR signalling regulation. This review describes the history, structure, and GPCR-dependent and independent functions of both protein families — and makes the case for systematic nomenclature to replace the historic names still in use for mammalian arrestins.
From the Masterclass Library
This week's featured course from the Masterclass Library: The Agonist Effect: A Story of Bias with Sam Hoare. Advanced quantitative approaches to understanding how ligands produce biased signaling — and what that means for how you interpret your own data.
What Members Say
The scientists in this community hold teaching to the same standard they hold the science.
"The content had enough depth to satisfy the hunger for theory while being full of practical knowledge."
— Dr. GPCR University Learner
About Dr. GPCR
Dr. GPCR is the intelligence and community platform for GPCR scientists. Premium members access the full Masterclass library, weekly curated publications, live sessions, and the Terry's Corner AMA series.
This Week in Premium
Premium Members are reading 18 publications this week, including a review on GRK and arrestin nomenclature and functions in GPCR-dependent and independent signalling. Plus 4 industry updates and 1 new event — GPCR Happy Hour, Boston, April 29.
Not a member yet? Try Premium for 14 days — $49 ➤
Comments